Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas

Cancer Journal

Volumn 12, Issue 3, 2006, Pages 229-236

  Kountourakis, Panteleimon ^a,b   Pavlakis, Kitty ^a   Psyrri, Amanda ^a,b   Rontogianni, Dimitra ^c   Xiros, Nikolaos ^a   Patsouris, Efstratios ^a   Pectasides, Dimitrios ^a   Economopoulos, Theofanis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b YALE CANCER CENTER   (United States)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Colorectal cancer; EGFR; Her 2 neu; Immunohistochemistry; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOPLASM; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33745116615     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200605000-00012     Document Type: Article

References (45)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481-488.
2. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes B vs Dukes' C colon cancer: results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04). J Clin Oncol 1999;17:1349-1355.
3. Midgley RS, Kerr DJ. Adjuvant treatment of colorectal cancer. Cancer Treat Rev 1997;23:135-152.
4. Olayioye M, Neve R, Lane H et al. The ERBB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167.
5. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor. J Clin Oncol 2003;21:2787-2799.
6. Yen L, You XL, AI Moustafa AE et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000;19:3460-3469.
7. Salomon D, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
8. Yasui W, Sumiyoshi H, Hata J et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988;48:137-141.
9. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807.
10. Menard S, Casalini M, Campiglio M, Pupa S et al. HER2 over-expression in various tumour types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 2001;12[suppl 1]:S15-S19.
11. Sainsbury JR, Needham GU, Farndon JR et al. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987;1(8547):1398-1402.
12. Toikkanen S, Helin H, Isola J et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow up. J Clin Oncol 1992;10:1044-1048.
13. Baselga J, Arteaga LC. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-2459.
14. Chung YK, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810.
15. Jacombs TW, Gowm AM, Yaziji H et al. Specificity of Hercep test in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-1987.
16. Agresti A. Categorical Data Analysis. New York: John Wiley & Sons, 1990.
17. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Assoc 1985;53:229-232.
18. Ooi A, Takehana T, Li X et al. Protein overexpression and gene amplification of Her-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004;17:895-904.
19. Spano JP, Lagorce C, Atlan D et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005;16:102-108.
20. Arnaout AH, Dawson PM, Soomro S et al. HER2 oncoprotein expression in colorectal adenocarcinoma: an immunohistochemical study using three different antibodies. J Clin Pathol 1992;45:726-727.
21. Kay EW, Mulcahy H, Walsh CB et al. Cytoplasmic C-erbB2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 1994;25:455-461.
22. Essapen S, Thomas H, Green M et al. The expression and prognostic significance of Her-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol 2004;24:241-248.
23. Atkins D, Reiffen KA, Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893-901.
24. Kay EW, Walsh BCJ, Cassidy M et al. C-erbB2 immunostaining: problems with interpretation. J Clin Pathol 1994;47:816-822.
25. Corbett IP, Henry JA, Angus B et al. NCL-B11, a new monoclonal antibody recognising the internal domain of the CERBB2 oncogene protein effective for use on formalin-fixed paraffin embedded tissue. J Pathol 1990;161:15-25.
26. Akiyama T, Sudo C, Ogawara H et al. The product of the human C-erbB2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-1646.
27. De Potter CR, Quatacuer J, Maertens G et al. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 1989;44:869-974.
28. D'Emilia J, Bulovas U, Wolf B et al. Expression of the C-erbB2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 1989;4:1233-1239.
29. Kapitanovic S, Radosevic S, Kapitanovic M et al. The expression of p185 HER-2/neu correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997;112:1103-1113.
30. Half E, Broaddus R, Danenberg KD et al. Her-2 receptor expression, localization and activation in colorectal cancer cell lines and human tumours. Int J Cancer 2004;108:540-548.
31. McKay JA, Murray LJ, Curran S et al. Evaluation of the epidermal growth factor receptor in colorectal tumours and lymph node metastases. Eur J Cancer 2002;38:2258-2264.
32. Mayer A, Takimoto M, Fritz E et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and MDR gene expression in colorectal cancer. Cancer 1993;71:2454-2460.
33. Nakae S, Shimada E, Urakawa T. Study of C-ERB-B-2 protein and epidermal growth factor receptor expression and DNA ploidy pattern in colorectal carcinoma. J Surg Oncol 1993;54:246-251.
34. Kluftinger AM, Robinson BW, Ouenville NF et al. Correlation of EGFR and C-ERBB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1992;1:97-105.
35. Steele RJL, Kelly P, Ellul B. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990;77:1352-1354.
36. Lazaris AC, Theodoropulos GE, Anastassopoulos P et al. Prognostic significance of p53 and erbb2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol 1995;10:661-668.
37. Essapen S, Thomas H, Green M et al. The expression and prognostic significance of Her-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol 2004;24:241-248.
38. McKay JA, Coane JF, Ross VG et al. C-ERBB2 is not a major factor in the development of colorectal cancer. Br J Cancer 2002;86:568-573.
39. Chamberlain NL, Ward RL, Hawkins NJ. Clinicopathological significance of CERB-B2 expression in colorectal carcinoma. Oncol Rep 1999;6:527-531.
40. Sun X-F, Carstensen JM, Stal O et al. c-erbB2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma. APMIS 1995;103:309-315.
41. Osako T, Miyahara M, Uchino S et al. Immunohistochemical study of C-ERBB2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998;55:548-555.
42. Shia J, Klimstra DS, Li RA et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 2005;18:1350-1356.
43. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-286.
44. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-1327.
45. Camp RL, Dolled-Filhart M, King BL et al. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003;63:1445-1448.